The most effective treatment at halting inflammation in patients with highly active multiple sclerosis (MS) is immune ablation followed by autologous hematopoietic stem cell transplantation (AHSCT). Better patient selection and supportive management, as well as advances in conditioning regimens have resulted in improved safety with AHSCT. However, which comorbidities or prior therapies increase the risks associated with AHSCT still need to be determined. In addition, there is still debate as to which AHSCT conditioning regimen offers the best balance of long-term efficacy and safety. New studies comparing AHSCT with highly effective disease-modifying therapies will help to inform on the ideal placement of AHSCT in the treatment algorithm. Currently, many centers are experienced and use AHSCT to treat select patients with MS, contributing to ongoing registries and clinical trials which will help answer these questions.
WallinMTCulpepperWJCampbellJD, et al. The prevalence of MS in the United States. Neurology2019; 92: e1029–e1040.
2.
GiovannoniGTurnerBGnanapavanS, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?Mult Scler Relat Disord2015; 4(4): 329–333.
3.
SormaniMPMuraroPASaccardiR, et al. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. Mult Scler2017; 23(2): 201–204.
4.
MuraroPAPasquiniMAtkinsHL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol2017; 74(4): 459–469.
5.
SharrackBSaccardiRAlexanderT, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Acc. Bone Marrow Transplant. Epub ahead of print 26 September 2019. DOI: 10.1038/s41409-019.
6.
RotsteinDLHealyBCMalikMT, et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol2015; 72(2): 152–158.
ChitnisTGonzalezCHealyBC, et al. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol2018; 5: 1478–1491.
9.
AtkinsH.Stem cell transplantation to treat multiple sclerosis. JAMA2019; 321: 153–155.
10.
BoseGThebaultSDXAtkinsHL, et al. Does resetting the immune system fix multiple sclerosis?Can J Neurol Sci. Epub ahead of print 12 September 2019. DOI: 10.1017/cjn.2019.294.
11.
AtkinsHFreedmanMS.Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis. Methods Mol Biol2009; 549: 231–246.
12.
CohenJABaldassariLEAtkinsHL, et al. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant2019; 25(5): 845–854.
13.
AtkinsHLBowmanMAllanD, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet2016; 388(10044): 576–585.
14.
NashRAHuttonGJRackeMK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology2017; 88(9): 842–852.
15.
SnowdenJABadoglioMLabopinM, et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv2017; 1(27): 2742–2755.
16.
MontalbanXGoldRThompsonAJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler2018; 24: 96–120.
17.
OntanedaD.Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS) (ClinicalTrials.gov Identifier: NCT03535298). Bethesda,D: National Library of Medicine, 24May2018.
18.
MowryEM.Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS) (ClinicalTrials.gov Identifier: NCT03500328). Bethesda, MD: National Library of Medicine, 18April2018.
19.
PolmanCHO’ConnorPWHavrdovaE, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354(9): 899–910.
20.
HavrdovaEArnoldDLCohenJA, et al. Alemtuzumab CARE-MS I 5-year follow-up. Neurology2017; 89: 1107–1116.
21.
ComiGCookSRammohanK, et al. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. Ther Adv Neurol Disord2018; 11: 1756285617753365.
22.
HauserSLBar-OrAComiG, et al. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med2017; 376: 221–234.
23.
BurtRKBalabanovRBurmanJ, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis. JAMA2019; 321(2): 165–174.
24.
CasanovaBJarqueIGascónF, et al. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. Neurol Sci2017; 38(7): 1213–1221.
25.
MooreJJMasseyJCFordCD, et al. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. J Neurol Neurosurg Psychiatry2019; 90(5): 514–521.
26.
ShevchenkoJLKuznetsovANIonovaTI.Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis : physician’s and patient’s perspectives. Ann Hematol2015; 94(7): 1149–1157.
27.
ThebaultSTessierDLeeH, et al. High serum neurofilament light chain normalises after haematopoietic stem cell transplant for MS. Neurol Neuroimmunol Neuroinflammation2019; 6: e598.
28.
BoseGAtkinsHLBowmanM, et al. Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis. Mult Scler2019; 25(13): 1764–1772.
29.
CarrerasEDufourCMohtyM, et al. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Cham: Springer, 2019.
SnarskiESnowdenJAOliveiraMC, et al. Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). Bone Marrow Transplant2015; 50(2): 216–220.
32.
Curro’DVuoloLGualandiF, et al. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: a MRI-based clinical study. Mult Scler2015; 21(11): 1423–1430.
33.
BurtRKBalabanovRHanX, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA2015; 313(3): 275–284.
34.
BurmanJIacobaeusESvenningssonA, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry2014; 85(10): 1116–1121.
35.
TolfAFagiusJCarlsonK, et al. Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation. Acta Neurol Scand2019; 140(5): 320–327.
36.
SaccardiRKozakTBocelli-TyndallC, et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler2006; 12(6): 814–823.
37.
HamerschlakNRodriguesMMoraesDA, et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplant2010; 45(2): 239–248.
38.
ChenBZhouMOuyangJ, et al. Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol Sci2012; 33(4): 881–886.
39.
MancardiGSormaniMDi GioiaM, et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler2012; 18(6): 835–842.
40.
MancardiGLSormaniMPGualandiF, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis A phase II trial. Neurology2015; 84(10): 981–988.
41.
XuJJiB-XSuL, et al. Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. Ann Hematol2011; 90(3): 343–348.
42.
MariottiniAInnocentiCForciB, et al. Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis. Eur J Neurol2019; 26(4): 624–630.
